To date, prostate cancer patients originally respond to the androgen ablation therapy but eventually succumb to disease. Collectively, the proposed explanations such as mutations of AR, the change of the steroid specificity of AR through AR mutations, or through AR interaction with coregulators, have been actively investigated. Furthermore, the induction of AR transactivation through the phosphorylation signal cascade may provide an alternative explanation of why the activation of AR is less dependent on androgens. Recently, the P.I. identified the HER2/Neu-MAP kinase-AR pathway. The growth of prostate cancer LNCaP cell could be increased through overexpression and activation of HER2/Neu. The P.I. has also found that the MAP kinase signal cascade could be the factor to active AR and the expression of prostate specific antigen (PSA) in the absence or in the presence of therapeutic concentrations of androgen. In the same report, the P.I. also delineated codon 514 on AR as the MAP kinase target site. The mutation of this MAP kinase site on AR reduced the AR transcriptional activity inside the cell. These results highlight the importance of MAP kinase on the in vivo AR transactivation. The AR is a transcription factor that belongs to the steroid receptor (SR) super-family. Recently, it has been reported that specific sets of proteins were recruited by the SRs as coregulators that may function as bridge factors between the receptors and general transcription factors in the preinitiation complex. Identifying and understanding the function of individual components of these complexes is crucial in determining how SRs regulate their target genes. Results from these studies suggested coactivators not only can enhance AR transcriptional activity, but may also be able to modulate the specificity of sex hormones or antiandrogens on AR-mediated transactivation in prostate cells. Our recent results have provided evidence to link MAP kinase signal to the AR function. It will be of great interest to know if the phosphorylation signal cascade can cross talk to the ARAs and consequently affect the ARA-AR mediated functions in prostate cancer. Therefore, we propose to study the following aims:
Aim 1 : Identification of in vivo phosphorylation sites in AR and demonstration of their linkage to the HER2/NeuIMAPK-induced AR transactivation.
Aim 2 : Investigating that phosphorylated AR (by HER2/Neu/MAPK) has a higher capacity to interact with ARAB.
Aim 3 : Demonstration that phosphorylated ARAs by HER2/Neu/MAPK have higher capacities to interact with AR.
Aim 4 : Staining of phosphorylated AR and ARAs in different stages of prostate cancer. The accomplishment of this study would provide valuable information of that how MAP kinase signal cross talk to AR and AR associated proteins in molecular mechanism and the pathogenesis of prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK060912-03
Application #
6646592
Study Section
Special Emphasis Panel (ZDK1-GRB-7 (O1))
Program Officer
Margolis, Ronald N
Project Start
2001-09-30
Project End
2005-08-31
Budget Start
2003-09-01
Budget End
2004-08-31
Support Year
3
Fiscal Year
2003
Total Cost
$279,125
Indirect Cost
Name
University of Rochester
Department
Internal Medicine/Medicine
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Yu, Shengqiang; Xia, Shujie; Yang, Diandong et al. (2013) Androgen receptor in human prostate cancer-associated fibroblasts promotes prostate cancer epithelial cell growth and invasion. Med Oncol 30:674
Yu, Shengqiang; Yeh, Chiuan-Ren; Niu, Yuanjie et al. (2012) Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblasts. Prostate 72:437-49
Ni, Jing; Mai, Tiejun; Pang, See-Tong et al. (2009) In vitro and in vivo anticancer effects of the novel vitamin E ether analogue RRR-alpha-tocopheryloxybutyl sulfonic acid in prostate cancer. Clin Cancer Res 15:898-906
Yin, Yi; Ni, Jing; Chen, Ming et al. (2009) RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects. Clin Cancer Res 15:190-200
Chen, Ming; Wolfe, Andrew; Wang, Xi et al. (2009) Generation and characterization of a complete null estrogen receptor alpha mouse using Cre/LoxP technology. Mol Cell Biochem 321:145-53
Chen, Ming; Ni, Jing; Zhang, Yong et al. (2008) ERAP75 functions as a coactivator to enhance estrogen receptor alpha transactivation in prostate stromal cells. Prostate 68:1273-82
Niu, Yuanjie; Yeh, Shuyuan; Miyamoto, Hiroshi et al. (2008) Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res 68:7110-9
Yin, Yi; Ni, Jing; Chen, Ming et al. (2007) The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3. Clin Cancer Res 13:2271-80
Ni, Jing; Pang, See-Too; Yeh, Shuyuan (2007) Differential retention of alpha-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells. Prostate 67:463-71
Zhang, Caixia; Yeh, Shuyuan; Chen, Yen-Ta et al. (2006) Oligozoospermia with normal fertility in male mice lacking the androgen receptor in testis peritubular myoid cells. Proc Natl Acad Sci U S A 103:17718-23

Showing the most recent 10 out of 19 publications